Compare CRNX & RH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | RH |
|---|---|---|
| Founded | 2008 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | 2018 | 2011 |
| Metric | CRNX | RH |
|---|---|---|
| Price | $84.97 | $146.61 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 14 |
| Target Price | $76.75 | ★ $167.00 |
| AVG Volume (30 Days) | ★ 2.4M | 536.5K |
| Earning Date | 05-07-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.31 |
| EPS | N/A | ★ N/A |
| Revenue | $1,039,000.00 | ★ $1,193,046,000.00 |
| Revenue This Year | $720.10 | $8.39 |
| Revenue Next Year | $184.67 | $9.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.52 |
| 52 Week Low | $32.30 | $106.30 |
| 52 Week High | $85.01 | $256.78 |
| Indicator | CRNX | RH |
|---|---|---|
| Relative Strength Index (RSI) | 89.88 | 39.40 |
| Support Level | $83.47 | $138.99 |
| Resistance Level | N/A | $161.18 |
| Average True Range (ATR) | 0.12 | 7.28 |
| MACD | -0.86 | -1.55 |
| Stochastic Oscillator | 93.85 | 18.39 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
RH is a luxury furniture and lifestyle retailer primarily operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories, including furniture, lighting, textiles, bath, decor, and is growing the presence of its hospitality business with 26 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Estates and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade via expanding abroad, its World of RH digital platform (highlighting offerings outside of home furnishings), and offerings in architecture, media, and more.